Antimalarials in rheumatic diseases
Identifieur interne : 003091 ( Main/Exploration ); précédent : 003090; suivant : 003092Antimalarials in rheumatic diseases
Auteurs : Susan Tett ; David Cutler ; Richard DaySource :
- Bailliere's Clinical Rheumatology [ 0950-3579 ] ; 1990.
English descriptors
- Teeft :
- Active therapy, Adverse effects, Adverse reactions, American journal, Antimalarial, Antimalarial drugs, Antimalarial therapy, Antirheumatic, Antirheumatic drugs, Arthritis, Biochemical pharmacology, Blood cells, Blood concentrations, British journal, Chloroquine, Chloroquine base, Chloroquine diphosphate, Chloroquine phosphate, Chloroquine therapy, Clinical pharmacology, Cutler, Daily dose, Diphosphate, Discoid lupus erythematosus, Disease state, Dos, Dosing, England journal, Erythematosus, European journal, Extensive accumulation, Grip strength, Gustafsson, Hydroxychloroquine, Hydroxychloroquine sulfate, Hydroxychloroquine sulphate, Hydroxychloroquine therapy, Large distribution volume, Lupus, Lupus erythematosus, Lymphocyte, Lysosomal, Lysosome, Mackenzie, Major improvement, Morning stiffness, Pharmacokinetic, Pharmacokinetic studies, Pharmacokinetics, Pharmacology, Placebo, Placebo therapy, Plasma clearances, Plasma concentrations, Renal clearance, Retinopathy, Retrospective study, Rheumatic, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatology, Scandinavian journal, Scherbel, Serum concentrations, Sulphate, Sulphate salt, Systemic lupus erythematosus, Tett, Therapeutic concentration range, Therapy, Toxicity, Tropical medicine.
Abstract
Summary: The antimalarials hydroxychloroquine and chloroquine remain established and effective agents for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Although the mechanisms of action remain uncertain, evidence is accumulating that the antirheumatic and immunological effects of the antimalarials are related to their massive distribution into the cellular acid-vesicle system. These drugs are attracting new interest because their relative safety recommends their use in early rheumatoid arthritis and as a component of second-line antirheumatic drug combinations. The absence of data examining the effect of antimalarials upon radiological progression of rheumatoid arthritis needs to be rectified. Recent understanding of the pharmacokinetics of these drugs reveals that steady-state concentrations are not achieved for at least 3–4 months. Preliminary information also suggests a relationship between blood concentrations and effect. Taken together, these data suggest that more effective dosage regimens will be possible when therapeutic concentration ranges are properly established.
Url:
DOI: 10.1016/S0950-3579(05)80004-4
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000004
- to stream Istex, to step Curation: 000004
- to stream Istex, to step Checkpoint: 001E62
- to stream Main, to step Merge: 003160
- to stream Main, to step Curation: 003091
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antimalarials in rheumatic diseases</title><author><name sortKey="Tett, Susan" sort="Tett, Susan" uniqKey="Tett S" first="Susan" last="Tett">Susan Tett</name></author><author><name sortKey="Cutler, David" sort="Cutler, David" uniqKey="Cutler D" first="David" last="Cutler">David Cutler</name></author><author><name sortKey="Day, Richard" sort="Day, Richard" uniqKey="Day R" first="Richard" last="Day">Richard Day</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F57636BAF3CF186DCF92FABCF180621E47F8D1DF</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/S0950-3579(05)80004-4</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-14X9QKCD-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000004</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000004</idno><idno type="wicri:Area/Istex/Curation">000004</idno><idno type="wicri:Area/Istex/Checkpoint">001E62</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E62</idno><idno type="wicri:doubleKey">0950-3579:1990:Tett S:antimalarials:in:rheumatic</idno><idno type="wicri:Area/Main/Merge">003160</idno><idno type="wicri:Area/Main/Curation">003091</idno><idno type="wicri:Area/Main/Exploration">003091</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antimalarials in rheumatic diseases</title><author><name sortKey="Tett, Susan" sort="Tett, Susan" uniqKey="Tett S" first="Susan" last="Tett">Susan Tett</name></author><author><name sortKey="Cutler, David" sort="Cutler, David" uniqKey="Cutler D" first="David" last="Cutler">David Cutler</name></author><author><name sortKey="Day, Richard" sort="Day, Richard" uniqKey="Day R" first="Richard" last="Day">Richard Day</name></author></analytic><monogr></monogr><series><title level="j">Bailliere's Clinical Rheumatology</title><title level="j" type="abbrev">BACR</title><idno type="ISSN">0950-3579</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="467">467</biblScope><biblScope unit="page" to="489">489</biblScope></imprint><idno type="ISSN">0950-3579</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0950-3579</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active therapy</term><term>Adverse effects</term><term>Adverse reactions</term><term>American journal</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Antimalarial therapy</term><term>Antirheumatic</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Biochemical pharmacology</term><term>Blood cells</term><term>Blood concentrations</term><term>British journal</term><term>Chloroquine</term><term>Chloroquine base</term><term>Chloroquine diphosphate</term><term>Chloroquine phosphate</term><term>Chloroquine therapy</term><term>Clinical pharmacology</term><term>Cutler</term><term>Daily dose</term><term>Diphosphate</term><term>Discoid lupus erythematosus</term><term>Disease state</term><term>Dos</term><term>Dosing</term><term>England journal</term><term>Erythematosus</term><term>European journal</term><term>Extensive accumulation</term><term>Grip strength</term><term>Gustafsson</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine sulfate</term><term>Hydroxychloroquine sulphate</term><term>Hydroxychloroquine therapy</term><term>Large distribution volume</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lymphocyte</term><term>Lysosomal</term><term>Lysosome</term><term>Mackenzie</term><term>Major improvement</term><term>Morning stiffness</term><term>Pharmacokinetic</term><term>Pharmacokinetic studies</term><term>Pharmacokinetics</term><term>Pharmacology</term><term>Placebo</term><term>Placebo therapy</term><term>Plasma clearances</term><term>Plasma concentrations</term><term>Renal clearance</term><term>Retinopathy</term><term>Retrospective study</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatology</term><term>Scandinavian journal</term><term>Scherbel</term><term>Serum concentrations</term><term>Sulphate</term><term>Sulphate salt</term><term>Systemic lupus erythematosus</term><term>Tett</term><term>Therapeutic concentration range</term><term>Therapy</term><term>Toxicity</term><term>Tropical medicine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: The antimalarials hydroxychloroquine and chloroquine remain established and effective agents for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Although the mechanisms of action remain uncertain, evidence is accumulating that the antirheumatic and immunological effects of the antimalarials are related to their massive distribution into the cellular acid-vesicle system. These drugs are attracting new interest because their relative safety recommends their use in early rheumatoid arthritis and as a component of second-line antirheumatic drug combinations. The absence of data examining the effect of antimalarials upon radiological progression of rheumatoid arthritis needs to be rectified. Recent understanding of the pharmacokinetics of these drugs reveals that steady-state concentrations are not achieved for at least 3–4 months. Preliminary information also suggests a relationship between blood concentrations and effect. Taken together, these data suggest that more effective dosage regimens will be possible when therapeutic concentration ranges are properly established.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Cutler, David" sort="Cutler, David" uniqKey="Cutler D" first="David" last="Cutler">David Cutler</name><name sortKey="Day, Richard" sort="Day, Richard" uniqKey="Day R" first="Richard" last="Day">Richard Day</name><name sortKey="Tett, Susan" sort="Tett, Susan" uniqKey="Tett S" first="Susan" last="Tett">Susan Tett</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003091 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003091 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F57636BAF3CF186DCF92FABCF180621E47F8D1DF
|texte= Antimalarials in rheumatic diseases
}}
| This area was generated with Dilib version V0.6.33. |  |